Showing results (1-10 of 11) with videos related to

Sort By:
Pageof 2
Journal of Gynecologic Oncology|February 7, 2022
HPV vaccination among seropositive, DNA negative cohorts: a systematic review & meta-analysisColm Mac Eochagain, Robert Power, Imelda Parker, et al.
JCO Precision Oncology|January 11, 2024
Modifiable Risk Factors and Risk of Colorectal and Endometrial Cancers in Lynch Syndrome: A Systematic Review and Meta-AnalysisRobert F Power, Damien E Doherty, Imelda Parker, et al.
Therapeutic Advances in Medical Oncology|September 13, 2021
Radium-223 in combination with enzalutamide in metastatic castration-resistant prostate cancer: a multi-centre, phase II open-label studyRaymond S McDermott, John Greene, John McCaffrey, et al.
BMC Cancer|January 17, 2024
Neoadjuvant trastuzumab deruxtecan (T-DXd) with response-directed definitive therapy in early stage HER2-positive breast cancer: a phase II study protocol (SHAMROCK study)Gavin P Dowling, Sinead Toomey, Philip Bredin, et al.
Leukemia & Lymphoma|September 20, 2017
Risk adjusted therapy in chronic lymphocytic leukemia: a phase II cancer trials Ireland (CTRIAL-IE [ICORG 07-01]) study of fludarabine, cyclophosphamide, and rituximab therapy evaluating response adapted, abbreviated frontline therapy with FCR in non-del(17p) CLLNiamh Appleby, David O'Brien, Fiona M Quinn, et al.
British Journal of Cancer|December 9, 2022
Efficacy and toxicity of primary re-irradiation for malignant spinal cord compression based on radiobiological modelling: a phase II clinical trialNeil D Wallace, Mary T Dunne, Orla McArdle, et al.
Acta Oncologica (Stockholm, Sweden)|June 5, 2025
TCHL - a phase II neo-adjuvant study assessing TCH (docetaxel, carboplatin and trastuzumab) and TCHL (docetaxel, carboplatin, trastuzumab and lapatinib) in HER-2 positive breast cancer patients: a 5-year follow-up with serum biomarker analysisJohn Crown, Alex J Eustace, Denis M Collins, et al.
British Journal of Cancer|March 12, 2020
Non-inferiority randomised phase 3 trial comparing two radiation schedules (single vs. five fractions) in malignant spinal cord compressionPierre G Thirion, Mary T Dunne, Paul J Kelly, et al.
Cancers|April 3, 2021
Phase Ib Trial of Copanlisib, A Phosphoinositide-3 Kinase (PI3K) Inhibitor, with Trastuzumab in Advanced Pre-Treated HER2-Positive Breast Cancer "PantHER"Niamh M Keegan, Simon J Furney, Janice M Walshe, et al.
The Lancet. Gastroenterology & Hepatology|September 21, 2023
Trimodality therapy versus perioperative chemotherapy in the management of locally advanced adenocarcinoma of the oesophagus and oesophagogastric junction (Neo-AEGIS): an open-label, randomised, phase 3 trialJohn V Reynolds, Shaun R Preston, Brian O'Neill, et al.
Pageof 2